Definium Therapeutics (NASDAQ:DFTX) Reaches New 1-Year High – Here’s What Happened

Shares of Definium Therapeutics, Inc. (NASDAQ:DFTX) hit a new 52-week high during trading on Friday . The company traded as high as $49.70 and last traded at $46.63, with a volume of 756709 shares. The stock had previously closed at $46.14.

Key Headlines Impacting Definium Therapeutics

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: Stifel Nicolaus initiated or reiterated a “Buy” rating on Definium Therapeutics, adding to the bullish analyst coverage surrounding the company. Definium Therapeutics Gets a Buy from Stifel Nicolaus
• Positive Sentiment: Piper Sandler reaffirmed its “Overweight” rating and raised its price target to $75 from $73. The new target implies substantial upside from the referenced share price of $46.14, potentially strengthening investor confidence in the company’s valuation and pipeline. Piper Sandler rating and price target update
• Positive Sentiment: Analysts collectively maintain a “Buy” consensus rating. The overall positive view may offset the impact of individual downgrades and provide support for DFTX shares. Definium Therapeutics Receives Consensus Buy Rating
• Neutral Sentiment: Definium reported its second-quarter 2026 financial results and highlighted recent business developments. Investors are likely focused on the company’s operating progress and cash resources as it continues developing its therapeutic programs. Definium Therapeutics Reports Second Quarter 2026 Results
• Negative Sentiment: Definium’s quarterly loss was worse than expected. The company reported adjusted EPS of negative $1.44 versus the consensus estimate of negative $0.55, a miss of $0.89 per share. The company is also expected to remain unprofitable for the full year, which could weigh on sentiment. Definium Therapeutics Q2 2026 Earnings Call Transcript
• Negative Sentiment: Wall Street Zen downgraded DFTX to “Sell,” creating a notable bearish counterpoint to the broader analyst optimism and potentially increasing volatility. Definium Therapeutics Cut to Sell at Wall Street Zen

Analysts Set New Price Targets

A number of equities research analysts have commented on DFTX shares. JonesTrading lifted their target price on shares of Definium Therapeutics from $61.00 to $74.00 and gave the stock a “buy” rating in a research report on Wednesday, June 24th. Royal Bank Of Canada reissued an “outperform” rating on shares of Definium Therapeutics in a report on Monday, June 22nd. Stifel Nicolaus raised their price target on Definium Therapeutics from $30.00 to $60.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Piper Sandler reaffirmed an “overweight” rating and issued a $75.00 price objective (up from $73.00) on shares of Definium Therapeutics in a report on Friday. Finally, Wall Street Zen cut Definium Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $55.00.

Definium Therapeutics Stock Performance

The stock has a fifty day moving average of $37.89 and a 200 day moving average of $25.87. The company has a market capitalization of $4.60 billion, a P/E ratio of -13.45 and a beta of 2.23. The company has a debt-to-equity ratio of 0.15, a quick ratio of 4.69 and a current ratio of 4.69.

Definium Therapeutics (NASDAQ:DFTX) last released its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.89). As a group, equities research analysts anticipate that Definium Therapeutics, Inc. will post -2.27 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Mark Sullivan sold 13,008 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total value of $585,750.24. Following the completion of the sale, the insider directly owned 320,571 shares of the company’s stock, valued at approximately $14,435,312.13. This represents a 3.90% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Robert Barrow sold 29,208 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $1,315,236.24. Following the sale, the chief executive officer owned 1,098,246 shares in the company, valued at approximately $49,454,017.38. The trade was a 2.59% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 48,096 shares of company stock valued at $2,165,763 in the last 90 days. Corporate insiders own 2.40% of the company’s stock.

Institutional Trading of Definium Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of DFTX. Russell Investments Group Ltd. lifted its stake in shares of Definium Therapeutics by 110.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock valued at $25,000 after buying an additional 2,003 shares in the last quarter. BNP Paribas Financial Markets increased its stake in Definium Therapeutics by 56.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock worth $55,000 after buying an additional 3,020 shares in the last quarter. Flagship Harbor Advisors LLC purchased a new stake in Definium Therapeutics in the 4th quarter worth $117,000. Caxton Associates LLP bought a new stake in Definium Therapeutics during the third quarter valued at about $126,000. Finally, Mercer Global Advisors Inc. ADV raised its holdings in Definium Therapeutics by 10.5% during the third quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company’s stock valued at $259,000 after acquiring an additional 2,079 shares during the period. 27.91% of the stock is owned by hedge funds and other institutional investors.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.